What’s Propelling Valeant Pharmaceuticals Intl Inc to Reach 52-Week Low?

 What's Propelling Valeant Pharmaceuticals Intl Inc to Reach 52 Week Low?

The stock of Valeant Pharmaceuticals Intl Inc (TSE:VRX) hit a new 52-week low and has $18.45 target or 8.00% below today’s $20.05 share price. The 7 months bearish chart indicates high risk for the $6.78B company. The 1-year low was reported on Nov, 8 by Barchart.com. If the $18.45 price target is reached, the company will be worth $542.40M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 911,672 shares traded hands. Valeant Pharmaceuticals Intl Inc (TSE:VRX) has declined 29.58% since April 1, 2016 and is downtrending. It has underperformed by 31.53% the S&P500.

Valeant Pharmaceuticals Intl Inc (TSE:VRX) Ratings Coverage

Out of 2 analysts covering Valeant Pharmaceuticals International (TSE:VRX), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. $74 is the highest target while $38 is the lowest. The $42.50 average target is 111.97% above today’s ($20.05) stock price. Valeant Pharmaceuticals International has been the topic of 14 analyst reports since October 20, 2015 according to StockzIntelligence Inc. On Tuesday, October 25 the stock rating was maintained by RBC Capital Markets with “Sector Perform”. The firm has “Outperform” rating by RBC Capital Markets given on Tuesday, January 26. As per Thursday, August 11, the company rating was maintained by TD Securities. The rating was maintained by RBC Capital Markets with “Sector Perform” on Monday, October 31. RBC Capital Markets maintained the stock with “Sector Perform” rating in Tuesday, September 20 report. The company was maintained on Wednesday, September 7 by RBC Capital Markets. The stock has “Sector Perform” rating given by RBC Capital Markets on Tuesday, October 11. The stock of Valeant Pharmaceuticals Intl Inc (TSE:VRX) has “Outperform” rating given on Tuesday, October 20 by RBC Capital Markets. RBC Capital Markets maintained it with “Sector Perform” rating and $74 target price in Friday, June 3 report. On Monday, June 20 the stock rating was maintained by RBC Capital Markets with “Sector Perform”.

More notable recent Valeant Pharmaceuticals Intl Inc (TSE:VRX) news were published by: Fool.com which released: “Why Valeant Pharmaceuticals Intl Inc Stock Is Slumping Today” on November 08, 2016, also Fool.com with their article: “Another Month, Another 27% Decline for Valeant Pharmaceuticals Intl. Inc. in …” published on November 07, 2016, Profitconfidential.com published: “Valeant Pharmaceuticals Intl Inc: Did VRX Stock Just Bottom?” on November 03, 2016. More interesting news about Valeant Pharmaceuticals Intl Inc (TSE:VRX) were released by: Fool.com and their article: “3 Figures in Focus When Valeant Pharmaceuticals Intl. Inc. Reports Its Q3 Results” published on November 01, 2016 as well as Investorplace.com‘s news article titled: “Why Valeant Pharmaceuticals Intl Inc (VRX), Allergan plc Ordinary Shares (AGN …” with publication date: November 02, 2016.

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The company has a market cap of $6.78 billion. The Firm is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It currently has negative earnings. It operates through two divisions: Developed markets and Emerging markets.

VRX.TO Company Profile

Valeant Pharmaceuticals International, Inc., incorporated on August 9, 2013, is a specialty pharmaceutical and medical device company. The Firm is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Firm operates through two divisions: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal (GI) disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses primarily on branded generics, OTC products and medical devices.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment